Marc-Olivier Geinoz – CEO, Dipharma SA

Dipharma SA is a Swiss specialty pharmaceutical company, developing improved generics medicines for rare metabolic diseases. Founder & CEO Marc-Olivier Geinoz discusses why the company has chosen to compete in the largely unexplored rare diseases generics space, its direct presence in the German market, and the opportunities inherent in metabolic disease small-molecules.  
The more I discovered the market needs in the orphan business, the more I got passionate about it; I realized we could do something great for the patients. This was enough for me to leave my position as CEO of a 500-employee CDMO to start a small company from scratch.
Become a PharmaBoardroom Member for free to access this content
Join the 35,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report